The consensus is that monogenic diseases — those involving only one gene — are the low-hanging fruit of the field.

For presumed monogenic diseases, the availability of multiple families with very similar clinical phenotypes substantially increases power for gene discovery.

A second major finding was that other genes may play an important contributing role in determining LDL levels even in monogenic FH patients.